Pharmacists Addressed Obesity Therapy Side Effects
Experts in Boston discussed managing GLP-1 side effects through dietary adjustments and ketone monitoring.
Updated on Sept. 28, 2026 in Weight Loss
Live Poll
Do you trust new medical monitoring devices to help manage your long-term health conditions?
At the 2026 New England Institute of Ambulatory Care Pharmacists Annual Forum in Boston, experts focused on helping patients maintain weight loss treatments. The discussion centered on preventing nausea through caloric control and using new monitoring tools.
Why it matters
Managing gastrointestinal adverse effects is critical for patient adherence to obesity therapies. Proper education on dietary habits and monitoring can help patients avoid the discontinuation of their treatment plans.
Clinical guidance suggests patients transition from consuming 3 or 4 slices of pizza to just 1 slice to accurately gauge fullness levels. This shift helps prevent the nausea associated with overeating while on GLP-1 therapy.
The players
Jennifer Goldman
She serves as a professor of pharmacy practice and the director of cardiometabolic services.
New England Institute of Ambulatory Care Pharmacists
This professional organization hosted its 2026 annual meeting in Boston to address clinical pharmacy practice.
The details
Pharmacists are now utilizing US-approved dual glucose-ketone monitors to help patients track metabolic health, which serves as a safeguard against the risk of diabetic ketoacidosis. By interpreting this data and providing specific dietary action plans, practitioners aim to help patients navigate the side effects of weight loss medications.
Timeline
The New England Institute of Ambulatory Care Pharmacists held its Annual Forum in 2026.
Health Landscape
The integration of advanced metabolic monitoring follows a pattern set by the FDA approval of dual glucose-ketone monitors, providing a new layer of clinical oversight for patients. This shift marks a departure from traditional reliance on subjective patient reporting toward data-driven therapeutic management.
Patients using GLP-1 therapies may find that moderating their food portions, such as limiting pizza intake, significantly reduces episodes of nausea. Those with access to dual glucose-ketone monitors should consult their pharmacists to create data-backed dietary action plans.
The takeaway
Maintaining obesity treatment requires both careful dietary monitoring and close coordination with clinical pharmacists to identify early warning signs of complications. Patients should view their caloric intake as a vital component of their overall therapy success.
Further reading
For more on managing treatment side effects, visit Weight Loss.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you trust new medical monitoring devices to help manage your long-term health conditions?
